Publications

Cell research

Social status impacts T-cell responses through synapse strength in the prefrontal cortex.

01-06-2026

Nature medicine

Publisher Correction: Clinical development of cancer vaccines.

01-04-2026

Nature reviews. Immunology

Guidelines for T cell nomenclature.

01-04-2026

Nature medicine

Clinical development of cancer vaccines.

01-03-2026

Nature cancer

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

01-03-2026

Nature communications

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

05-02-2026

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Key Publication

Nature

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

01-12-2025

Communications medicine

Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.

30-09-2025

Immuno-oncology technology

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

01-09-2025

Cancer research

Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis.

16-06-2025

Cancer cell

Learning the language of T cell receptors through large-scale screening.

09-06-2025

bioRxiv : the preprint server for biology

A functionally validated TCR-pMHC database for TCR specificity model development.

12-05-2025

Cancer immunology research

Natural Killer Cell-Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia.

04-03-2025

Nature biotechnology

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

01-02-2025

bioRxiv : the preprint server for biology

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition.

28-01-2025

Nature communications

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

14-01-2025

Frontiers in immunology

Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system.

08-01-2025

Nature medicine

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

01-11-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

Journal of immunology (Baltimore, Md. : 1950)

ITPK1 Sensitizes Tumor Cells to IgA-dependent Neutrophil Killing In Vivo.

15-10-2024

Nature

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy.

01-08-2024

Cancer discovery

IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity.

01-07-2024

Cancer discovery

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.

01-07-2024

Cell reports

Gene and protein sequence features augment HLA class I ligand predictions.

25-06-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

Science (New York, N.Y.)

DNA damage induces p53-independent apoptosis through ribosome stalling.

17-05-2024

Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-05-2024

Nature reviews. Clinical oncology

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.

01-03-2024

Nature medicine

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-02-2024

Cancer cell

Distinct spatiotemporal dynamics of CD8⁺ T cell-derived cytokines in the tumor microenvironment.

08-01-2024

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Cancer discovery

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

05-10-2023

STAR protocols

Protocol for ex vivo culture of patient-derived tumor fragments.

16-06-2023

Nature biotechnology

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.

01-06-2023

Cancer immunology, immunotherapy : CII

The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer.

01-06-2023

Nature communications

DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age.

17-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

01-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Cell reports. Medicine

An adverse tumor-protective effect of IDO1 inhibition.

21-02-2023

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Key Publication

BMC cancer

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

30-12-2022

The New England journal of medicine

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

08-12-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.

14-11-2022

Med (New York, N.Y.)

Next generation T cell therapies for solid cancers.

14-10-2022

Cancer discovery

When Cancer Cells Become the Enablers of an Antitumor Immune Response.

05-10-2022

Immuno-oncology technology

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

01-09-2022

Nature immunology

Author Correction: Replicative history marks transcriptional and functional disparity in the CD8⁺ T cell memory pool.

01-07-2022

Nature reviews. Immunology

The precursors of CD8⁺ tissue resident memory T cells: from lymphoid organs to infected tissues.

01-05-2022

Nature immunology

Replicative history marks transcriptional and functional disparity in the CD8⁺ T cell memory pool.

01-05-2022

Social status impacts T-cell responses through synapse strength in the prefrontal cortex.

Publisher Correction: Clinical development of cancer vaccines.

Guidelines for T cell nomenclature.

Clinical development of cancer vaccines.

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis.

Learning the language of T cell receptors through large-scale screening.

A functionally validated TCR-pMHC database for TCR specificity model development.

Natural Killer Cell-Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia.

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition.

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system.

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

ITPK1 Sensitizes Tumor Cells to IgA-dependent Neutrophil Killing In Vivo.

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy.

IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity.

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.

Gene and protein sequence features augment HLA class I ligand predictions.

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

DNA damage induces p53-independent apoptosis through ribosome stalling.

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment.

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

Protocol for ex vivo culture of patient-derived tumor fragments.

Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.

The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer.

DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age.

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

An adverse tumor-protective effect of IDO1 inhibition.

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.

Next generation T cell therapies for solid cancers.

When Cancer Cells Become the Enablers of an Antitumor Immune Response.

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

Author Correction: Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool.

The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues.

Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool.

This site uses cookies

Distinct spatiotemporal dynamics of CD8⁺ T cell-derived cytokines in the tumor microenvironment.

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.

Author Correction: Replicative history marks transcriptional and functional disparity in the CD8⁺ T cell memory pool.

The precursors of CD8⁺ tissue resident memory T cells: from lymphoid organs to infected tissues.

Replicative history marks transcriptional and functional disparity in the CD8⁺ T cell memory pool.